The Critical Relationship Between Regulatory Affairs and Regulatory Operations

There is a scenario that plays out more often than most people in the industry want to admit. A sponsor has done everything right scientifically. The data is solid. The regulatory strategy is sound. The submission plan has been in place for months. And then, in the final stretch, something breaks down. It’s not in the science or the strategy, but in the space between the team that designed the submission and the team that must build it.

A technical rejection. A missed deadline. A validation failure that could have been caught three weeks earlier if the right people had been talking to each other.

This is the handoff problem that lives at the intersection of two functions: regulatory affairs and regulatory operations.

Understanding what each function does, and where one ends and the other begins, is one of the most practical things a sponsor can do to protect submission quality and timelines.

The Role of Regulatory Affairs

Regulatory affairs (RA) sits at the intersection of strategy and science within life sciences organizations. According to the Regulatory Affairs Professionals Society, regulatory affairs professionals ensure their companies comply with all applicable laws and regulations, advise on regulatory aspects that could affect the business, and work with regulatory authorities on issues affecting their products and programs.

In practical terms, this means RA owns the what and the why of a submission. They determine the regulatory pathway, whether a product will pursue an NDA, BLA, or IND route, what data will be needed to support approval, and how the dossier should be framed to tell the most compelling scientific story to the agency. They author or oversee the content development: clinical overviews, nonclinical summaries, briefing documents, and labeling negotiations. They manage the agency relationship directly and typically manage the preparation for agency meetings and responses to information requests. They also make judgment calls about strategy that will affect the product's path for years.

The work of regulatory affairs is upstream, contextual, and often years in the making before a single eCTD sequence number is assigned.

The Role of Regulatory Operations

Regulatory Operations is often referred to as RO, reg ops, or regulatory publishing.  This team takes the content that Regulatory Affairs manages and turns it into a compliant, validated, submittable package. Where RA focuses on what goes into the submission and why, reg ops is responsible for how it gets built and that it reaches the agency correctly.

This is not a simple, clerical function. The FDA's eCTD Technical Conformance Guide includes dozens of pages of specifications governing everything from document granularity and folder structure to hyperlinking requirements, leaf titles, and XML backbone construction. Meeting those requirements consistently, across every sequence in a product's lifecycle, requires deep technical expertise and operational discipline.

Regulatory Operations also owns the eCTD structure. This includes sequence planning, lifecycle operations (replacements, appends, deletions), granularity decisions, metadata, and validation against FDA's submission standards. They manage the submission timeline from a publishing perspective, coordinate document ingestion, operate the publishing tools, and transmit the final package through the FDA's Electronic Submissions Gateway (ESG). Post-submission, they track receipt confirmation, monitor for technical issues, and maintain the lifecycle record of every application.

The work of regulatory operations is downstream, technical, and time-pressured.

Where These Functions Overlap and Where Things Break Down

The line between RA and RO is clear in theory. In practice, there is a zone of shared responsibility and it can be the source of critical submission issues across the lifecycle.

Submission planning is the most important example. Decisions about how to structure a sequence, what documents to include, how to handle amendments, and how to stage updates over a product's lifecycle require input from both functions. RA understands the regulatory intent; RO understands the technical constraints. Neither can make the best decisions without the other.

When this collaboration is missing the results are predictable. Documents arrive too late for proper validation. Granularity decisions get made without considering lifecycle implications. Structural choices that seem reasonable on paper create challenges three sequences into the future.

Common friction points in practice include:

• Late document delivery: RA may be working toward content deadlines that don't account for publishing time, QC cycles, and validation

• Granularity misalignment: Documents may be structured in ways that don't match the eCTD hierarchy, requiring last-minute rework

• Lifecycle blind spots: The team may be assuming they will use sequence strategies that don't account for how current decisions affect future amendments or supplements

• Agency request surprises: RA receiving a Complete Response Letter or Information Request without looping in reg ops until submission deadlines are already tight

Why the Handoff Is the Highest-Risk Moment

The moment strategy becomes structure is also the moment where errors become expensive.

The FDA's guidance on electronic submissions makes clear that sponsors are responsible for the completeness and technical compliance of everything they submit. A technically deficient package can result in a refuse-to-file (RTF) action, delaying the review clock entirely. More commonly, structural issues generate technical rejections or agency questions that are costly to resolve once review has begun. Again, this scenario is not because the science is wrong, but because the submission was not built correctly.

The earlier RO is brought into the conversation, the lower this risk. Involving the publishing team at the submission planning stage before documents are drafted, means that lifecycle decisions, granularity choices, and document delivery timelines are all made with full knowledge of the technical requirements. This is a necessary discipline regardless of company size.

The Optimal Regulatory Affairs-Regulatory Operations Relationship

The best submission programs we work with at WAYS share a few consistent characteristics.

Regulatory Operations is in the room early. The publishing team takes part in submission planning discussions, not just execution. When sequence strategy, amendment scope, or module organization are being decided, the people who will build the submission have a voice.

There is a shared submission management plan. Both functions are working from the same document that captures deliverable timelines, sequence strategy, document responsibilities, and QC checkpoints. This plan is actively maintained, not created once and filed away.

Document delivery timelines are built backwards from the submission date. RA and RO agree on cut-off dates for final documents that account for publishing, QC review, validation, and a reasonable buffer. Deadlines set only by the submission date, without factoring in publishing time, are not real deadlines.

Communication is ongoing. There are regular touchpoints throughout the sequence build, not just at intake and at submission. Status updates, flags for emerging issues, and early warnings about document delays are part of the workflow, not exceptions to it.

High-functioning RA and RO teams also learn from each other over time. Publishers who understand the regulatory rationale behind a submission make better structural decisions. RA professionals who understand technical constraints make better content decisions. That cross-functional fluency doesn't happen by accident. It is built through consistent collaboration and it compounds over time. Every well-run submission makes the next one faster, cleaner, and easier to execute.

A Note for Companies That Outsource Regulatory Publishing

When a sponsor outsources regulatory publishing for a submission, their vendor usually functions as their RO team for that submission. The same principles apply, with an added dimension: the handoff now crosses organizational boundaries.

This means the quality of communication, the clarity of the submission plan, and the shared understanding of roles and expectations matter even more than they do within a single organization. A publishing vendor who operates as a transactional document processor, receiving files and returning a package, is not the same as one who functions as an integrated Regulatory Operations partner. The difference shows up in submission quality, in the ability to anticipate and resolve issues before they escalate, and in the coherence of a product's lifecycle record over time.

The WAYS team has worked alongside regulatory teams across INDs, NDAs, BLAs, and complex lifecycle programs. In our experience, the submissions that go most smoothly are not necessarily the simplest ones. They are the ones where RA and RO, whether internal or outsourced, are operating as a single coordinated function from the beginning.

The Bottom Line

Regulatory affairs and regulatory operations are distinct disciplines with distinct skill sets. Treating them as interchangeable, or as a handoff rather than a collaboration, is one of the most common and preventable sources of submission problems in the industry.

The quality of a submission reflects not just the science behind it, but the relationship between the team that designed it and the team that built it. Getting that relationship right is important work.

About WAYS Pharmaceutical Services  WAYS is a regulatory publishing and submission management partner specializing in eCTD submissions for life sciences sponsors. Our team has supported INDs, NDAs, BLAs, and lifecycle programs across a wide range of clients. Learn more about our submission management services →